Toxicity · palliative participants with esophageal and GE‐junction carcinoma previously treated with chemotherapy
It is very uncertain whether summary of findings table (subcomparison 2): second‐line… changes toxicity compared with control intervention alone (very low certainty).
1 finding from 1 review
Toxicity · palliative participants with esophageal and GE‐junction carcinoma
It is very uncertain whether summary of findings table (subcomparison 3): chemotherapy agent(s)… changes toxicity compared with control intervention alone (very low certainty).
1 finding from 1 review
Toxicity · palliative participants with esophageal and GE‐junction carcinoma
It is very uncertain whether summary of findings table (subcomparison 4): targeted therapy agent… changes toxicity compared with control intervention alone (very low certainty).
1 finding from 1 review
Toxicity · palliative participants with esophageal and GE‐junction carcinoma
It is very uncertain whether summary of findings table: chemotherapy or targeted therapy agent(s)… changes toxicity compared with control intervention alone (very low certainty).
1 finding from 1 review
Toxicity · palliative participants with esophageal and GE‐junction carcinoma
It is very uncertain whether summary of findings table (subcomparison 1): chemotherapy or… changes toxicity compared with BSC (very low certainty).
1 finding from 1 review
Toxicity · palliative participants with AC of the esophagus
It is very uncertain whether summary of findings table (subcomparison 5): chemotherapy or… changes toxicity compared with control intervention alone (very low certainty).
1 finding from 1 review
Toxicity · palliative participants with SCC of the esophagus
It is very uncertain whether summary of findings table (subcomparison 6): chemotherapy or… changes toxicity compared with control intervention alone (very low certainty).
1 finding from 1 review
Adverse events ‐ neurotoxicity Diagnosed by clinicians · patients with oesophageal cancer
Active cancer therapy combined with TCM showed no clear difference in adverse events ‐ neurotoxicity Diagnosed by clinicians compared with active cancer therapy (low certainty).
1 finding from 1 review
Adverse events ‐ cardiac toxicity Diagnosed by clinicians · patients with oesophageal cancer
Active cancer therapy combined with TCM showed no clear difference in adverse events ‐ cardiac toxicity Diagnosed by clinicians compared with active cancer therapy (low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
It is very uncertain whether irinotecan changes treatment discontinuation due to toxicity compared with non‐irinotecan‐containing regimens (very low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
Docetaxel showed no clear difference in treatment discontinuation due to toxicity compared with non‐docetaxel‐containing regimens (low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
Capecitabine showed no clear difference in treatment discontinuation due to toxicity compared with 5‐FU‐containing regimens (low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
It is very uncertain whether oxaliplatin changes treatment discontinuation due to toxicity compared with the same regimen including cisplatin (very low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment discontinuation due to toxicity compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
S‐1 showed no clear difference in treatment discontinuation due to toxicity compared with 5‐FU‐containing regimens (high certainty).
1 finding from 1 review